Compared to last year, we delivered solid top-line growth during the quarter despite cash constraints and the distraction of raising capital," Karen Zaderej, Chief Executive Officer of AxoGen.
Alachua, FL (PRWEB) November 07, 2012
Third Quarter 2012 Highlights
•Revenues increased 74% to $1.98 million from $1.14 million reported third quarter 2011
•Gross profit increased to $1.44 million from $10,000 reported third quarter 2011
•Gross profit margins improved to 73% compared to 0.9% for the same period in 2011 and remained strong for the nine months ended September 30, 2012 at 74%.
•$20.8 million in proceeds from financing with PDL BioPharma, Inc. closed post third quarter
AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions, today announced revenues for the third quarter ended September 30, 2012 of $1.98 million, a 74% increase over revenues of $1.14 million in the third quarter 2011 .
“Compared to last year, we delivered solid top-line growth during the quarter despite cash constraints and the distraction of raising capital,” commented Karen Zaderej, Chief Executive Officer of AxoGen. “In addition, to remain in compliance with covenants imposed by our former lender, we carefully managed cash and chose to defer certain sales force growth and marketing activities.”
Ms. Zaderej continued, “As a result of the recent financing with PDL, we paid off all bank debt and eliminated the restrictive lender requirements. This will allow us the flexibility to develop and expand our sales force and invest in significant marketing efforts.”
Revenues for the period were $1.98 million, a 74% increase, compared to $1.14 million for the same period in 2011. These results were due to expansion of sales and marketing efforts versus third quarter 2011 and focused on the development of new accounts as well as penetration into key accounts.
Revenues decreased 1.5% compared to second quarter 2012 revenues of $2.01 million. This is the second year in which the third quarter has been relatively flat compared to the second quarter. While this may suggest seasonality in peripheral nerve surgery, it is important to note that in both of these quarters there were material corporate transactions that may have distracted operations. In addition, during the period, the Company made personnel changes in certain sales territories, but did not increase the size of its direct sales force.
Gross profit for the period increased to $1.44 million from the reported third quarter 2011 results of $10,000. The favorable result reflects increased revenues and lower manufacturing costs in 2012 and excludes an inventory write-off of $0.83 million which occurred during the third quarter 2011.
The gross profit margin for the period increased to 73% compared to 0.9% for the same quarter last year.
Sales and Marketing Expenses
During the period sales and marketing expenses increased to $1.70 million from $1.11 million reported during the same period last year. The increase was the result of the Company’s increased support for its sales force and an increase in the number of direct sales persons. As of October 31, 2012, the Company had 17 direct and 24 independent sales representatives and distributors.
Research and Development Expenses
Research and development expenses increased to $0.39 million during the quarter, compared to $0.23 million reported during the same period last year. Substantially all of the research and development expenses relate to expenditures for clinical activity.
General and Administrative Expenses
General and administrative expenses increased to $1.39 million for the period, compared to $1.30 million reported in the same quarter last year. These expenses were principally an increase in payroll and benefits as the Company hired additional personnel to support its sales growth.
Loss From Operations and Net Loss
The Company reported loss from operations for third quarter of 2012 of $2.04 million, compared to the reported loss from operations of $2.63 million during the same period in 2011.
The net loss for the period decreased to $2.24 million, or $0.20 per common share, from a net loss of $3.11 million, or $2.60 per common share, reported during the third quarter of 2011.
At September 30, 2012, the Company had $4.4 million in cash and cash equivalents, with approximately $6.6 million in debt outstanding.
On October 5, 2012, the Company entered into a Revenue Interests Purchase Agreement with PDL BioPharma Inc., under which the Company received $20.8 million in cash. Certain proceeds of which were used to repay existing debt and expenses related to the transaction.
As of November 1, 2012, the Company had $15.8 million in cash and equivalents and no bank debt outstanding.
Earnings Call Information
As previously announced, AxoGen, Inc. management will review third quarter 2012 financials during a conference call scheduled for November 8, 2012 at 11:00 AM Eastern Time. The conference call information is as follows:
Conference dial-in: 877-709-8150
International dial-in: 201-689-8354
A webcast replay of the conference call will be available under the “Investor” tab on the Company's website, http://www.axogeninc.com.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at http://www.axogeninc.com.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.